Claims for Patent: 8,906,606

Summary for Patent: 8,906,606

Title:	Method of predicting and reducing risk of metastasis of breast cancer to lung
Abstract:	A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.
Inventor(s):	Gupta; Gaorav P. (New York, NY), Massague; Joan (New York, NY), Minn; Andy J. (New York, NY)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:	13/447,684
Patent Claims:	1. A method for evaluating breast cancer tissue derived from a patient, comprising the steps of: (a) obtaining a sample of breast cancer tissue from the patient, (b) evaluating the sample of breast cancer tissues to determine expression levels of plurality of genes selected from the group consisting of SPARC, IL13RA2, KLRC1 and KLRC2, MMP1, KYNU, EREG, TNC, ISG20, ALDH3A1, KRTHB1, PTGS2, LAPTM5, C10orf116, ROBO1, SPANXC, ANGPTL4, FSCN1, SOX4, SPANXB1 and SPANXC, COL6A1, CXCL1, MMP2, STOM, GPR153, MAN1A1, C14orf139, CASP1, IGSF4, LTBP1, NR2F1, EMP1, ID1, CNOT2, VCAM1, OLFML2A, NEDD9, CSF2RA, MOCOS, EPHX1, MBNL2, LOC388483, GSN, MYH10, ARNT2, RARRES3, EFEMP1, MATN2, LY6E, HLA-DPA1, ASMTL, ABCC3, KIAA1199, CXCR4, and PARD6B to obtain a sample signature for the cancer tissue sample, wherein the evaluation is performed by a method selected from the group consisting of binding of complementary oligonucleotide probes, RT-PCR, nucleic acid microarray analysis, binding of RNA specific antibodies, protein-ligand binding assays, protein immunoassays and protein microarray assays, and (c) comparing the sample signature to a reference signature, wherein the reference signature defines a standard expression level for each gene and a significant change direction for each gene, wherein the significant change direction is upregulation if the gene is SPARC, IL13RA2, KLRC1 and KLRC2, MMP1, KYNU, EREG, TNC, ISG20, ALDH3A1, KRTHB1, PTGS2, LAPTM5, C10orf116, ROBO1, SPANXC, ANGPTL4, FSCN1, SOX4, SPANXB1 and SPANXC, COL6A1, CXCL1, MMP2, STOM, GPR153, MAN1A1, C14orf139, CASP1, IGSF4, LTBP1, NR2F1, EMP1, ID1, CNOT2, or VCAM1 and downregulation if the gene is OLFML2A, NEDD9, CSF2RA, MOCOS, EPHX1, MBNL2, LOC388483, GSN, MYH10, ARNT2, RARRES3, EFEMP1, MATN2, LY6E, HLA-DPA1, ASMTL, ABCC3, KIAA1199, CXCR4, or PARD6B, and wherein a difference in the expression level in the sample signature that differs from the reference signature level for the gene in the significant change direction for the gene for at least a predetermined number of the genes tested is indicative that the patient has an increased risk of lung metastasis of the breast cancer. 2. The method of claim 1, wherein the plurality of genes includes the genes FSCN1, MMP1, ANGPTL4, C10orf116, CXCL1, PTGS2, KRTHB1, VCAM1, RARRES3, LTBP1, KYNU, CXCR4, LY6E, ID1, MAN1A1, NEDD9, and EREG. 3. The method of claim 2, wherein the plurality of genes further includes the gene TNC. 4. The method of claim 2, wherein the predetermined number is 10. 5. The method of claim 2, wherein the predetermined number is 15. 6. The method of claim 3, wherein the predetermined number is 10. 7. The method of claim 3, wherein the predetermined number is 15. 8. A method for treating breast cancer in a patient to reduce the risk of lung cancer metastasis, comprising the steps of: evaluating breast cancer tissue derived from a patient by a method comprising the steps of: (a) obtaining a sample of breast cancer tissue from the patient, (b) evaluating the sample of breast cancer tissues to determine expression levels of plurality of genes selected from the group consisting of SPARC, IL13RA2, KLRC1 and KLRC2, MMP1, KYNU, EREG, TNC, ISG20, ALDH3A1, KRTHB1, PTGS2, LAPTM5, C10orf116, ROBO1, SPANXC, ANGPTL4, FSCN1, SOX4, SPANXB1 and SPANXC, COL6A1, CXCL1, MMP2, STOM, GPR153, MAN1A1, C14orf139, CASP1, IGSF4, LTBP1, NR2F1, EMP1, ID1, CNOT2, VCAM1, OLFML2A, NEDD9, CSF2RA, MOCOS, EPHX1, MBNL2, LOC388483, GSN, MYH10, ARNT2, RARRES3, EFEMP1, MATN2, LY6E, HLA-DPA1, ASMTL, ABCC3, KIAA1199, CXCR4, and PARD6B to obtain a sample signature for the cancer tissue sample, and (c) comparing the sample signature to a reference signature, wherein the reference signature defines a standard expression level for each gene and a significant change direction for each gene, wherein the significant change direction is upregulation if the gene is SPARC, IL13RA2, KLRC1 and KLRC2, MMP1, KYNU, EREG, TNC, ISG20, ALDH3A1, KRTHB1, PTGS2, LAPTM5, C10orf116, ROBO1, SPANXC, ANGPTL4, FSCN1, SOX4, SPANXB1 and SPANXC, COL6A1, CXCL1, MMP2, STOM, GPR153, MAN1A1, C14orf139, CASP1, IGSF4, LTBP1, NR2F1, EMP1, ID1, CNOT2, or VCAM1 and downregulation if the gene is OLFML2A, NEDD9, CSF2RA, MOCOS, EPHX1, MBNL2, LOC388483, GSN, MYH10, ARNT2, RARRES3, EFEMP1, MATN2, LY6E, HLA-DPA1, ASMTL, ABCC3, KIAA1199, CR4, or PARD6B, and wherein a difference in the expression level in the sample signature that differs from the reference signature level for the gene in the significant change direction for the gene for at least a predetermined number of the genes tested is indicative that the patient has an increased risk of lung metastasis of the breast cancer, and if the evaluation indicates an increased risk of lung metastasis, treating the patient to reduce the risk of lung cancer metastasis with a therapeutic combination comprising at least two agents, wherein the agents are inhibitors of a protein selected from the group consisting of SPARC, IL13R.alpha.2, VCAM1, MMP1, MMP2, ID1, CXCL1, PTSG2 and EREG. 9. The method of claim 8, wherein the therapeutic combination comprises a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2. 10. The method of claim 9, wherein the first agent is an oligonucleotide. 11. The method of claim 9, wherein the second agent is an oligonucleotide. 12. The method of claim 9, wherein the first agent is a small molecule inhibitor. 13. The method of claim 9, wherein the first agent is selected from the group consisting of Erbitux, Iressa and Tarceva. 14. The method of claim 8, wherein the therapeutic combination comprises at least three agents that are inhibitors of a protein selected from the group consisting of SPARC, IL13R.alpha.2, VCAM1, MMP1, MMP2, ID1, CXCL1, PTSG2 and EREG. 15. The method of claim 14, wherein the therapeutic combination comprises agents effective to inhibit activity of MMP1, MMP2 and PTGS2. 16. The method of claim 15, wherein the therapeutic combination comprises a small molecule inhibitor of PTGS2 activity. 17. The method of claim 14, wherein the therapeutic combination comprises oligonucleotide agents effective to inhibit activity of MMPI and MMP2. 18. The method of claim 17, wherein the oligonucleotide agents are Seq ID No. 7 and seq ID No. 8.

Details for Patent 8,906,606

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2025-01-05
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2025-01-05